Levi & Korsinsky Investigates Fairness of Revance Therapeutics Acquisition by Crown Laboratories
On February 28, 2025, Levi & Korsinsky, LLP, a prominent securities litigation firm, announced that it has initiated an investigation into the proposed acquisition of Revance Therapeutics Inc (RVNC) by Crown Laboratories, Inc. (Crown). This investigation focuses on whether the acquisition price is fair to Revance stockholders.
Background:
Revance Therapeutics is a biotechnology company specializing in the development and commercialization of novel injectable therapies. On August 11, 2024, Revance announced that it had entered into a definitive agreement to be acquired by Crown for approximately $2.1 billion. Under the terms of the agreement, Revance stockholders will receive $40.50 in cash for each share of Revance common stock they hold.
The Investigation:
Levi & Korsinsky’s investigation centers on whether the proposed acquisition is in the best interests of Revance stockholders, considering the potential misalignment of interests between the Company’s management and its shareholders. The firm is examining the process by which Crown conducted its valuation of Revance and whether all relevant information was disclosed to stockholders.
Impact on Revance Stockholders:
The outcome of this investigation could significantly impact Revance stockholders who sold their shares prior to the acquisition announcement on August 11, 2024. If it is determined that the acquisition price was unfair, these stockholders may be eligible to recover damages. Conversely, if the investigation finds no wrongdoing, stockholders will have no recourse.
Impact on the World:
The impact of this investigation goes beyond Revance stockholders. The outcome could set a precedent for future mergers and acquisitions, potentially leading to increased scrutiny and higher standards of disclosure. Additionally, it could influence the broader biotech industry, as investors and regulators watch closely to see how this situation unfolds.
Conclusion:
The investigation into the fairness of the Revance Therapeutics acquisition by Crown Laboratories raises important questions about the process by which companies are valued and whether shareholders are receiving a fair deal. The outcome of this investigation could have far-reaching implications, not only for Revance stockholders but also for the biotech industry as a whole. As the situation develops, Levi & Korsinsky will continue to provide updates on this investigation.
- Levi & Korsinsky has commenced an investigation into the fairness of the Revance Therapeutics acquisition by Crown Laboratories.
- The investigation focuses on the potential misalignment of interests between the Company’s management and its shareholders.
- The outcome of the investigation could significantly impact Revance stockholders who sold their shares prior to the acquisition announcement.
- The investigation could set a precedent for future mergers and acquisitions, potentially leading to increased scrutiny and higher standards of disclosure.
- The biotech industry will be closely watching the outcome of this investigation.
